ABSTRACT Because ergonovine appears to produce coronary contractions by a serotonergic (5-HT) mechanism, we attempted to prevent ergonovine-induced ischemia in patients with vasospastic angina by pretreatment with ketanserin, a new selective 5-HT blocker. We studied seven patients with consistently positive results of ergonovine testing (ST segment elevation in three and ST segment depression in four). Ergonovine testing was performed before and after a bolus of 10 mg of ketanserin (all patients) and infusion of 2 to 4 mg/hr for 8 hr (six patients). To assess 5-HT blockade during ketanserin infusion, the constrictor response of hand veins to 5-HT was tested before and after ketanserin. Despite evidence of 5-HT blockade in hand veins, ergonovine-induced ischemia was not prevented by ketanserin in any patient, and there was no significant change in the dose of ergonovine required to provoke ischemia. In one patient, four spontaneous episodes of ST segment elevation occurred during infusion of ketanserin. The plasma concentrations of ketanserin at the time of ergonovine testing ranged from 61 to 127 ng/ml (mean 102) and were well above those that completely inhibit canine coronary 5-HT contractions in vitro. Although human coronary arteries may differ in their responsiveness to 5-HT or ketanserin, these data suggest that ischemia from ergonovine-induced coronary vasospasm is not mediated by 5-HT receptors. Circulation 70, No. 2, 178-183, 1984. CORONARY arterial spasm is now recognized as an important cause of ischemia in patients with all degrees of severity of coronary artery disease,' but the mechanisms responsible for its occurrence are still unknown. Ergonovine is the vasoconstrictor that most consistently provokes spasm in patients with angina at rest, 2 3 whose arteries appear hypersensitive to the drug at the site of spasm.4 Therefore the mechanism of ergonovine's action may be related to the cause ( 178 tagonist with no partial agonist activity,'" provides an opportunity to test whether ergonovine-induced vasospasm in patients with angina is mediated by 5-HT receptors. In this study we attempted to block the effects of ergonovine by pretreatment with ketanserin in seven patients with ergonovine-induced ischemia. In six of the patients we also assessed the level of 5-HT blockade in peripheral veins during infusion of ketanserin by a test of venoconstriction in the hand.
CORONARY arterial spasm is now recognized as an important cause of ischemia in patients with all degrees of severity of coronary artery disease,' but the mechanisms responsible for its occurrence are still unknown. Ergonovine is the vasoconstrictor that most consistently provokes spasm in patients with angina at rest, 2 3 whose arteries appear hypersensitive to the drug at the site of spasm.4 Therefore the mechanism of ergonovine's action may be related to the cause (or causes) of spontaneously occurring spasm. Recent work in experimental animals has shown that coronary arterial contractions induced by ergonovine are mediated by serotonergic (5-HT) receptors5-7 and that the increased sensitivity of atherosclerotic rabbit aortas to ergonovine is at least partially mediated by a 5-HT mechanism.8 5-HT receptors that mediate contraction have also been demonstrated recently in isolated human coronary arteries.9 ]0 tagonist with no partial agonist activity,'" provides an opportunity to test whether ergonovine-induced vasospasm in patients with angina is mediated by 5-HT receptors. In this study we attempted to block the effects of ergonovine by pretreatment with ketanserin in seven patients with ergonovine-induced ischemia. In six of the patients we also assessed the level of 5-HT blockade in peripheral veins during infusion of ketanserin by a test of venoconstriction in the hand.
Methods
Patient selection. Seven patients with angina pectoris and an ischemic electrocardiographic response to ergonovine maleate formed the study group. Their clinical, electrocardiographic, and angiographic findings are summarized in table 1. In five patients angina occurred both at rest and during exertion, while one patient had angina only at rest and another only during exertion. Ergonovine provoked chest pain and ST segment changes (elevation in three, depression in four) on at least two occasions in all patients. In four patients. (Nos. 2, 3, 4, and 6) coronary spasm after ergonovine was documented at angiographic examination (see figure 1) , while in three patients (Nos. 3, 4, and 7) myocardial dysfunction during ergonovine-induced ST segment changes was confirmed by technetium-labeled blood pool scintigraphy. Informed consent for the studies was obtained from each patient.
Ergonovine administration. All ergonovine tests were performed at least 48 hr after the cessation of treatment with calcium antagonists and long-acting nitrates. Sublingual nitrates were used as required for chest pain. No patient was receiving CIRCULATION figure 3 . These electrocardiographic changes were identical to those seen in other spontaneous ischcmic episodes and to those that accomiipanied crgonovine-induLced coronary arterial spasm at angiographic examination (figure 1). In this patient ketanserin did not prevent either spontaneous or ergonovine-iniduced ischermi a.
Results of hand senoconstriction tests. The venoconstriction curves of patient 5. who had a marked response to ketanserin, are shown in fiuLres 2A and 2B. The curves in figure 2A hand vein response. There was no contraction after 10 ng of 5-HT and only a small response of 600 VCU after 100 ng of 5-HT. The data points for 5-HT and norepinephrine tests from this patient are plotted in the form of dose-response curves in figure 4A . Ketanserin produced an approximately 15-fold parallel shift to the right of the dose-response curve to 5-HT but only a fourfold displacement of the norepinephrine curve. Figure 4B shows the dose-response curves for patient 6, in whom ketanserin had a less marked effect on the 5-HT-induced contractions and no effect on norepinephrine-induced contractions. Because there was no parallel displacement of the 5-HT dose-response curve, the effect of ketanserin has been expressed in terms of the percent reduction of the maximum 5-HT contraction (in this case 40%). The changes in doseresponse curves for 5-HT and norepinephrine in the six patients during infusion of ketanserin are shown in table 3. Three patients showed parallel rightward displacement of the 5-HT dose-response curve, and three showed only a reduction in the maximum contraction. Patients with the highest baseline sensitivity to 5-HT (minimum 5-HT dose to produce contraction of 1 or 10 ng) showed a greater response to ketanserin than those with lower baseline sensitivity to 5-HT (minimum 5-HT dose to produce contraction of 100 or 1000 ng).
The response of norepinephrine-induced contractions to ketanserin was always less marked than that of 5-HT-induced contractions, and in four of the patients ketaserin had no effect, indicating partial receptor specificity. The cold-pressor test induced only small contractions, and these were reduced in four of the patients during infusion of ketanserin.
Discussion
The demonstration of 5-HT-mediated contraction in human coronary arteries and the ability of 5-HT blockers to abolish ergonovine-induced coronary contractions in animals suggested that 5-HT blockade might prevent ergonovine-induced coronary vasospasm. In our study, however, 5-HT blockade with ketanserin did not prevent ergonovine-induced ischemia in any patient and had no effect on the dose of ergonovine required to provoke ischemia. This suggests that in patients, ergonovine-induced ischemia may not be mediated by coronary 5-HT receptors. It has recently been suggested that ergonovine-induced contractions in isolated human coronary arteries may not be mediated exclusively by 5-HT receptors and that there is partial involvement of an a-adrenergic membrane receptor.9 This possibility is unlikely to account for our negative results with ketanserin because the a-blocker phentolamine does not prevent ergonovine-induced spasm in patients with variant angina. '9 Our anecdotal finding that ketanserin did not prevent spontaneous ischemia in one patient suggests that *Bertrand M: Personal communication. spontaneous vasospasm is also not mediated by 5-HT receptors. This finding has been confirmed in a preliminary report of a double-blind, placebo-controlled, cross-over study of five patients with variant angina. In that study there was no effect of ketanserin on spontaneous ischemic episodes, despite evidence of inhibition of 5-HT platelet aggregation by the drug. 20 Clinical implications. Although the negative results of this study do not illuminate the cause (or causes) of coronary arterial spasm, the elimination of potential suspects such as a-adrenergic stimuli,3 thromboxane,21 prostacyclin deficiency,22 and now serotonin may help narrow the field in the search for the elusive underlying mechanism.
